{"url_path":"/sec/cik-0001119643/10-k/2026/item-3","section_key":"item-3","section_title":"Item 3 Legal Proceedings**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1119643/0001493152-26-024641-index.html","accession_number":"0001493152-26-024641","cik":"0001119643","ticker":null,"issuer_name":"NUTRA PHARMA CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1119643/0001493152-26-024641-index.html","primary_entity_key":"0001119643","primary_entity_name":"NUTRA PHARMA CORP"},"word_count":1012,"has_tables":true,"body_markdown":"**Item\n3. Legal Proceedings**\n\n** **\n\nMarc\nWeller v. Nutra Pharma Corporation, Case No. CACE-24-018346\n\n** **\n\nIn\nJanuary 2026, the Company entered into a settlement agreement with Marc Weller resolving litigation in Broward County, Florida. Pursuant\nto the settlement, the Company agreed to cancel and extinguish outstanding notes with an aggregate carrying value of approximately $175,000\nin exchange for $20,000 in cash (payable in installments through April 2026) and the issuance of 60 million shares of common stock.\n\n \n\nCSA\n8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150\n\n \n\nOn\nOctober 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida\n(Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. The Company filed\nits Answer and Affirmative Defenses on November 1, 2018, and asserted counterclaims against the plaintiff and certain related parties.\nMediation was held on June 21, 2019 but did not result in a resolution at that time. The dispute remained ongoing until it was resolved\nthrough settlement in May 2025.\n\n \n\nOn\nMay 19, 2025, the parties settled the case; fully resolving all existing disputes and conflicts between the parties. We agreed to pay\n$35,000 to the plaintiff(s) on or before May 19, 2025 and make nine (9) monthly payments of $10,000 each, beginning on June 19, 2025.\nThe case was dismissed on May 20, 2025 and all payments have been made as agreed. \n\n \n\n26\n\n \n\n \n\nSecurities\nand Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus\n\n \n\nOn\nSeptember 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit (the “SEC Action”)\nin the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and\nMr. McManus. After various motions to dismiss directed to the original Complaint and the First Amended Complaint filed May 29, 2019 were\ndisposed of in the SEC Action, the SEC filed the Second Amended Complaint against the Company and Messrs. Deitsch and McManus on April\n30, 2020 which became the operative pleading seeking permanent injunctive relief, disgorgement of ill-gotten gains and prejudgment interest\nthereon, civil monetary penalties, a permanent officer and director bar, and a permanent penny stock bar for alleged violations between\nAugust 2013 and June 2018 of the registration, broker-dealer registration, periodic reporting, insider reporting, anti-fraud, and anti-manipulation\nprovisions of the federal securities laws. After approximately four years of litigating the Second Amended Complaint, the Company and\nMessrs. Deitsch and McManus agreed to settle the case by entering into consents, without admitting or denying the allegations of the\nSecond Amended Complaint except as to personal and subject matter jurisdiction, to entry of Final Judgments.\n\n \n\nOn\nMarch 19, 2024, the United States District Court for the Eastern District of New York in the SEC Action, approved bifurcated settlements\nin the form of consent judgments (the “Consent Judgments”) entered by the District Court wherein the Company and Messrs.\nDeitsch and McManus, without admitting or denying the allegations of the Complaint except as to personal and subject matter jurisdiction,\nresolved all liability issues and certain remedies as to each Defendant and left open other issues relating to remedies regarding the\nappropriateness and amount of disgorgement, prejudgment interest, and/or civil penalties to be paid as to all Defendants, and whether\na penny stock bar shall be imposed against Defendant McManus, and if so, the length of any such bar, for later resolution by the District\nCourt upon motion or further settlement. The Consent Judgments, among other things:\n\n \n\n(1)\nPermanently enjoin Defendant Nutra Pharma from committing violations of the federal securities laws that the SEC has alleged in this\ncase, including violations of Sections 5(a), 5(c), and 17(a) of the Securities Act of 1933 (the “Securities Act”), Sections\n10(b) and 13(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and Rules 10b-5, 13a-11, and 13a-13 thereunder;\n\n \n\n(2)\nPermanently enjoin Defendant Deitsch from committing violations of the federal securities laws that the SEC has alleged in this case,\nincluding violations of Sections 5(a), 5(c), and 17(a) of the Securities Act, Sections 9(a)(2), 10(b), 13(a), 13(d), and 16(d) of the\nSecurities Exchange Act, and Rules 10b-5, 13a-14, 13d-2, and 16a-3 thereunder; impose a three-year officer-and-director bar on Deitsch,\npursuant to 15 U.S.C. §§ 77t(e) and 78u(d)(2); and impose a three-year penny-stock bar on Deitsch, pursuant to 15 U.S.C. §\n78u(d)(6); and\n\n \n\n(3)\nPermanently enjoin Defendant McManus from committing violations of the federal securities laws that the SEC has alleged in this case,\nincluding violations of Section 17(a) of the Securities Act and Sections 10(b) and 15(a) of the Exchange Act and Rule 10b-5 thereunder.\n\n \n\nOn\nMay 13, 2024, the remaining remedies regarding disgorgement, prejudgment interest, and civil penalties as to Defendant Deitsch and disgorgement,\nprejudgment interest, civil penalties, and a penny stock bar as to Defendant McManus were resolved by respective consents from each,\nwithout admitting or denying the allegations of the Complaint except as to jurisdiction and Section XIII of their respective Final Judgments\nthat restated the permanent injunctive relief, three-year officer-and-director bar on Deitsch, the three-year penny- stock bar on Deitsch\nfor the alleged violations described above from the Consent Judgments and imposed disgorgement of $44,046, prejudgment interest of $5,013,\nand a civil money penalty of $30,000 against Deitsch (a total of $79,060); and that restated the permanent injunctive relief and imposed\ntwo-year penny-stock bar against McManus, and imposed disgorgement of $5,500, prejudgment interest of $626, and a civil money penalty\nof $5,500 against McManus (a total of $11,626).\n\n \n\nOn\nAugust 28, 2024, the remaining remedies regarding disgorgement, prejudgment interest, and civil penalties as to the Company were resolved\nby consent by the Company, without admitting or denying the allegations of the Complaint except as to jurisdiction, in its Final Judgment\nthat restated the permanent injunctive relief against the Company for the alleged violations described above from the Consent Judgment\nand imposed disgorgement of $520,940, prejudgment interest of $59,295, and a civil money penalty of $100,000 against Nutra Pharma (a\ntotal of $680,235)."}